ESTRO35 Programme Book

ECKERT & ZIEGLER BEBIG S.A.

5200

EPIDOS

7030

Rue Jules Bordet 7180 Seneffe Belgium

Lesna 7, 900 28 Ivanka pri Dunaji Slovakia Viera Bocankova epiqaQA@epidos.eu www.epidos.eu

+32 6452 08 11 +32 6452 08 01 info @bebig.eu www.bebig.eu

ESTRO - EUROPEAN SOCIETY 3000 FOR RADIOTHERAPY AND ONCOLOGY Rue Martin V, 40 1200 Brussels Belgium

ELEKTA

200 - 500

Box 7593 10393 Stockholm Sweden

Gert van Santen +46 8 587 25400 +46 8 587 25500 info.europe@elekta.com www.elekta.com

+32 2 775 93 40 +32 2 779 54 94 info@estro.org www.estro.org

Elekta is a human care company pioneering significant innovations and clinical solutions for treating cancer and brain disorders. The company develops advanced tools and treatment planning systems for radiation therapy, radiosurgery and brachytherapy, as well as workflow enhancing software systems across the cancer care spectrum. Through its products and services, Elekta aims to improve, prolong and save patient lives. Elekta solutions in oncology and neurosurgery are used in over 6,000 hospitals globally. Elekta, with corporate headquarters in Stockholm, Sweden, employs approximately 3,000 people globally.

Founded in 1980, the European SocieTy for Radiotherapy and Oncology, ESTRO, is a non-profit and scientific organisation that advances all aspects of radiation oncology in order to improve patients’ care in the multimodality treatment of cancer. With over 6,500 members in and outside Europe, ESTRO supports all the radiation oncology professionals in their daily practice: radiation oncologists, medical physicists, radiobiologists, RTT (radiation therapists) and the wider oncology community. In order to achieve this, the Society promotes education, science dissemination and access to radiotherapy through its courses and workshops, conferences, publications and public affairs activities.

ELSEVIER BV

3000

Radarweg 29 1043 NX Amsterdam The Netherlands Nikki Weaver + 31 20 485 3510

n.weaver@elsevier.com www.elsevier.com

PROGRAMME AND EXHIBITION GUIDE | EXHIBITION

379